PharmGen Science, Inc. Statistics
Want to see KR:004720 full AI Analyst Report?
PharmGen Science, Inc. (004720) Stock Statistics & Valuation Metrics
Total Valuation
PharmGen Science, Inc. has a market cap or net worth of KRW 68.40B. The enterprise value is KRW 45.24B.
- Market Cap
- KRW 68.40B
- Enterprise Value
- KRW 45.24B
Share Statistics
PharmGen Science, Inc. has 22,654,366 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 22,654,366
- Owned by Insiders
- ―
- Owned by Institutions
- 0.27%
Financial Efficiency
PharmGen Science, Inc.’s return on equity (ROE) is -0.80 and return on invested capital (ROIC) is 2.76%.
- Return on Equity (ROE)
- -0.80
- Return on Assets (ROA)
- -0.60
- Return on Invested Capital (ROIC)
- 2.76%
- Return on Capital Employed (ROCE)
- 0.04
- Revenue Per Employee
- 755.78M
- Profits Per Employee
- -509.35M
- Employee Count
- 229
- Asset Turnover
- 0.89
- Inventory Turnover
- 2.25
Valuation Ratios
The current PE Ratio of PharmGen Science, Inc. is -0.49. PharmGen Science, Inc.’s PEG ratio is 0.00.
- PE Ratio
- -0.49
- PS Ratio
- 0.39
- PB Ratio
- 0.47
- Price to FCF
- 4.55
- Price to Operating Cash Flow
- 3.84
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, PharmGen Science, Inc. had revenue of 173.07B and earned -116.64B in profits. Earnings per share was -5312.85.
- Revenue
- 173.07B
- Gross Profit
- 109.13B
- Operating Income
- 5.99B
- Pretax Income
- -151.10B
- Net Income
- -116.64B
- EBITDA
- 10.53B
- Earnings Per Share (EPS)
- -5312.85
Cash Flow
In the last 12 months, operating cash flow was 17.33B and capital expenditures -2.39B, giving a free cash flow of 14.94B billion.
- Operating Cash Flow
- 17.33B
- Free Cash Flow
- 14.94B
- Free Cash Flow per Share
- 675.35
Dividends & Yields
PharmGen Science, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 21.84%
- Earnings Yield
- -200.78%
Stock Price Statistics
- Beta
- -0.07
- 52-Week Price Change
- -26.93%
- 50-Day Moving Average
- 2872.50
- 200-Day Moving Average
- 3367.55
- Relative Strength Index (RSI)
- 64.73
- Average Volume (3m)
- 18.61K
Important Dates
PharmGen Science, Inc. upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
PharmGen Science, Inc. as a current ratio of 2.85, with Debt / Equity ratio of 4.10%
- Current Ratio
- 2.85
- Quick Ratio
- 2.01
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- -1.51
- Interest Coverage Ratio
- 4.30
Taxes
In the past 12 months, PharmGen Science, Inc. has paid -34.46B in taxes.
- Income Tax
- -34.46B
- Effective Tax Rate
- 0.23
Enterprise Valuation
PharmGen Science, Inc. EV to EBITDA ratio is 5.77, with an EV/FCF ratio of 3.32.
- EV to Sales
- 0.28
- EV to EBITDA
- 5.77
- EV to Free Cash Flow
- 3.32
- EV to Operating Cash Flow
- 2.86
Balance Sheet
PharmGen Science, Inc. has KRW 20.05B in cash and marketable securities with KRW 698.13M in debt, giving a net cash position of KRW 19.35B billion.
- Cash & Marketable Securities
- KRW 20.05B
- Total Debt
- KRW 698.13M
- Net Cash
- KRW 19.35B
- Net Cash Per Share
- KRW 854.31
- Tangible Book Value Per Share
- KRW 6,006.99
Margins
Gross margin is 64.26%, with operating margin of 2.22%, and net profit margin of -76.62%.
- Gross Margin
- 64.26%
- Operating Margin
- 2.22%
- Pretax Margin
- -96.69%
- Net Profit Margin
- -76.62%
- EBITDA Margin
- 4.90%
- EBIT Margin
- 2.22%
Analyst Forecast
The average price target for PharmGen Science, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 0.42%
- EPS Growth Forecast
- -4001.63%
Scores
- Smart Score
- ―
- AI Score
- 50

